Journal of the American Medical Informatics Association : JAMIA
Mar 1, 2025
OBJECTIVES: Clinical trials (CTs) are essential for improving patient care by evaluating new treatments' safety and efficacy. A key component in CT protocols is the study population defined by the eligibility criteria. This study aims to evaluate the...
Journal of the American Medical Informatics Association : JAMIA
Nov 1, 2024
OBJECTIVE: The objective of our research is to conduct a comprehensive review that aims to systematically map, describe, and summarize the current utilization of artificial intelligence (AI) in the recruitment and retention of participants in clinica...
Studies in health technology and informatics
Aug 22, 2024
We applied natural language processing (NLP) to a corpus extracted from 4 hours of expert panel discussion transcripts to determine the sustainability of a Stage II-III clinical trial of online social support interventions for Hispanic and African Am...
Advances in experimental medicine and biology
Jan 1, 2024
This chapter highlights the intersection of pain neuromodulation and machine learning (ML), exploring current limitations in pain management and how ML techniques can address these challenges. Neuromodulation technologies, such as spinal cord stimula...
PURPOSE: Matching patients to clinical trials is cumbersome and costly. Attempts have been made to automate the matching process; however, most have used a trial-centric approach, which focuses on a single trial. In this study, we developed a patient...
Glioblastoma (GBM) is the most malignant and lethal intracranial tumor, with extremely limited treatment options. Immunotherapy has been widely studied in GBM, but none can significantly prolong the overall survival (OS) of patients without selection...
Alkaptonuria (AKU, OMIM: 203500) is an autosomal recessive disorder caused by mutations in the Homogentisate 1,2-dioxygenase (HGD) gene. A lack of standardized data, information and methodologies to assess disease severity and progression represents ...
PURPOSE: Early discontinuation affects more than one third of patients enrolled in early-phase oncology clinical trials. Early discontinuation is deleterious both for the patient and for the study, by inflating its duration and associated costs. We a...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.